Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A Phase II FONICAP trial

Cancer

Volumn 79, Issue 10, 1997, Pages 1897-1902

  Pennucci, Maria Cristina ^a   Ardizzoni, Andrea ^a   Pronzato, Paolo ^b   Fioretti, Marina ^c   Lanfranco, Claudio ^d   Verna, Anna ^a   Giorgi, Guglielmina ^a   Vigani, Antonella ^b   Frola, Carlo ^e   Rosso, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Ospedale Civile   (Italy)

^e Ospedale Evangelico Internazionale   (Italy)

Author keywords

chemotherapy; cisplatin; doxorubicin; mitomycin; pleural mesothelioma

Indexed keywords

CISPLATIN; DOXORUBICIN; MITOMYCIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DYSPNEA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MALE; NEUROTOXICITY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHEST PAIN; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; DYSPNEA; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCINS; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; REMISSION INDUCTION;

EID: 0030919371     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970515)79:10<1897::AID-CNCR9>3.0.CO;2-D     Document Type: Article

References (21)

1. Silverberg E. Cancer statistics 1985. CA Cancer J Clin 1985; 351:19-35.
2. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345:535-9.
3. Doll R, Peto J. Asbestos. Effects of early exposure to asbestos. Health & Safety Commission. London: Her Majesty's Stationery Office, 1985.
4. Antman KH, Li FP, Osten R, Sugarbaker DJ, Herman T, Weissman C, et al. Mesothelioma: update to 3rd edition. In: DeVita VT Jr., Helleman S, Rosenberg SA, editors. (Cancer: principles and practice of oncology. 3rd edition.) Philadelphia PA: J.B. Lippincott, 1989:1-16.
5. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med 1980;303:200-2.
6. Brady LW. Mesothelioma: the role of radiation therapy. Semin Oncol 1981;8:329-34.
7. Butchart E, Ashcroft T, Barnsky W, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976;31:15-24.
8. Hansen AK, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991; 28:319-30.
9. Vogelzang NJ. Malignant mesothelioma: diagnostic and management strategies foe 1992. Semin Oncol 1992; 19(Suppl 11):64-71.
10. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, DePalma M, et al: Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant mesothelioma. Cancer 1991;67:2984-7.
11. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987;71:857-8.
12. Chahinian AP, Norton L, Holland JF, Szrajer L, Hart RD. Experimental and clinical activity of mitomycin C and cis-diamminedicloroplatinum in malignant mesothelioma. Cancer Res 1984;44:1688-92.
13. Chahinian AP, Antman K, Gautsou M, Carson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993; 11:1559-65.
14. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1990;47:207-14.
15. Simon R. Optimal two stage design for phase II clinical trials. Control Clin Trials 1989;10:1-10.
16. Lerner HJ, Schoenfeld DA, Martin A. Malignant mesothelioma. The Eastern Cooperative Group (ECOG) experience. Cancer 1983;52:1981-5.
17. Samson MK, Baker LH, Benjamin RS, Lane M, Plager C. cis-Dichlorodiamminoplatinum in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study. Cancer Treat Rep 1979;63:2027-9.
18. Dabouis G, Mevel BL, Corroller J. Treatment of diffuse pleural malignant mesothelioma by cis dichloro diammine platinum (CDDP) in nine patients. Cancer Chemother Pharmacol 1981;5:209-10.
19. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711-2.
20. Zidar BL, Pugh RP, Schiffer LM, Raju RN, Vaidya KA, Bloom RL, et al. Treatment of six of mesothelioma with doxorubicin and cisplatin. Cancer 1983;52:1788-91.
21. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J. Phase II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 1988;11:118-20.